AngioDynamics, Inc. (NASDAQ:ANGO) Files An 8-K Results of Operations and Financial Condition

On March 30, 2017, AngioDynamics, Inc. (AngioDynamics or
the Company) issued a press release announcing financial
results for the fiscal third quarter ended February 28, 2017. A
copy of the press release is attached hereto as Exhibit 99.1.

The information set forth in Item 2.02 of this Form 8-K
(including Exhibit 99.1) shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.

Forward-Looking Statements

This document and its attachments contains forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements regarding
AngioDynamics expected future financial position, results of
operations, cash flows, business strategy, budgets, projected
costs, capital expenditures, products, competitive positions,
growth opportunities, plans and objectives of management for
future operations, as well as statements that include the words
such as expects, reaffirms, intends, anticipates, plans,
believes, seeks, estimates, optimistic, or variations of such
words and similar expressions, are forward-looking statements.
These forward looking statements are not guarantees of future
performance and are subject to risks and uncertainties. Investors
are cautioned that actual events or results may differ from
AngioDynamics expectations. Factors that may affect the actual
results achieved by AngioDynamics include, without limitation,
the ability of AngioDynamics to develop its existing and new
products, technological advances and patents attained by
competitors, infringement of AngioDynamics technology or
assertions that AngioDynamics technology infringes the technology
of third parties, the ability of AngioDynamics to effectively
compete against competitors that have substantially greater
resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials,
overall economic conditions, the results of on-going litigation,
challenges with respect to third-party distributors or joint
venture partners or collaborators, the results of sales efforts,
the effects of product recalls and product liability claims,
changes in key personnel, the ability of AngioDynamics to execute
on strategic initiatives, the effects of economic, credit and
capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the
effects on pricing from group purchasing organizations and
competition, the ability of AngioDynamics to integrate purchased
businesses, as well as the risk factors listed from time to time
in AngioDynamics SEC filings, including but not limited to its
Annual Report on Form 10-K for the year ended May 31, 2016 and
its quarterly reports on Form 10-Q for the fiscal periods ended
August 31, 2016 and November 30, 2016. AngioDynamics does not
assume any obligation to publicly update or revise any
forward-looking statements for any reason.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.